0

Explore original, structured summaries for research and education.

Research profile

Cagrilintide(AM833)

(AM833)

Cagrilintide(AM833) is indexed as a Amylin receptor agonist research entry. Its current evidence category is (AM833), and published discussion commonly places it within Weight Loss, Metabolic. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.

Weight LossMetabolic

Identity

Molecular Data

Molecular weight
4,409.01 Da
Chain length
37 amino acids
Type
Amylin receptor agonist
Reported half-life
~7 days (159-195 hours)
Amino-acid sequence37-amino acid peptide

Literature map

Research indications

Weight Loss

  • Obesity (Monotherapy)effective
  • Obesity (CagriSema Combination)most effective
  • Weight Loss in Diabetic Patientsmost effective

Metabolic

  • Glycemic Controlmost effective
  • Insulin Sensitivityeffective

Appetite Control

  • Satiety Enhancementeffective

Evidence-gated guidance

Dosing Protocols

No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.

Dose
Not established on this profile
Frequency
Not established on this profile
Cycle
Not established on this profile
Storage
Follow the exact supplier or authorized product documentation; requirements vary by formulation
Open peptide calculator →

Combination risks

Interactions

Evidence status

No independently verified interaction table is available here for Cagrilintide(AM833). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.

Do not infer compatibility

Being listed beside another compound does not mean that combining them is safe or effective.

Evidence-informed overview

What to Expect

Evidence boundary

Research indications describe topics studied in the literature; they do not predict an individual outcome.

Clinical monitoring

Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.

Risk overview

Side Effects & Safety

The safety profile of Cagrilintide(AM833) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.

Verification

Quality Checklist

  1. Confirm exact chemical identity, sequence, salt form, and concentration.
  2. Require a batch-specific certificate of analysis with named test methods and results.
  3. Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
  4. For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.

Clear answers

Frequently Asked Questions

Is Cagrilintide(AM833) approved for personal use?

This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.

Why is no dose listed?

A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.

Do research indications prove effectiveness?

No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.

Source trail

References

  1. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityNovo Nordisk REDEFINE 1 Investigators · New England Journal of Medicine · 2025
  2. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesNovo Nordisk REDEFINE 2 Investigators · New England Journal of Medicine · 2025
  3. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialFrias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Machineni S, Mathieu C, Pedersen SD, Davies M · The Lancet · 2023

View the structural source profile ↗